Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

Journal of Clinical Investigation

Volumn 118, Issue 9, 2008, Pages 3132-3142

  Hacein Bey Abina, Salima ^a,b   Garrigue, Alexandrine ^b   Wang, Gary P ^c   Soulier, Jean ^d   Lim, Annick ^e   Morillon, Estelle ^b   Clappier, Emmanuelle ^e   Caccavelli, Laure ^a   Delabesse, Eric ^f   Beldjord, Kheira ^b,g   Asnafi, Vahid ^b,g   MacIntyre, Elizabeth ^b,g   Dal Cortivo, Liliane ^a   Radford, Isabelle ^b   Brousse, Nicole ^g   Sigaux, François ^d   Moshous, Despina ^a   Hauer, Julia ^b   Borkhardt, Arndt ^h   Belohradsky, Bernd H ⁱ   Wintergerst, Uwe ⁱ   Velez, Maria C ^j   Leiva, Lily ^j   Sorensen, Ricardo ^j   Wulffraat, Nicolas ^k   Blanche, Stéphane ^a   Bushman, Frederic D ^c   Fischer, Alain ^a,b   Cavazzana Calvo, Marina ^a,b   more..

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e INSTITUT PASTEUR   (France)

^f CHU PURPAN   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ASPARAGINASE; BMI1 PROTEIN; CORTICOSTEROID; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DAUNORUBICIN; IMMUNOGLOBULIN; METHOTREXATE; NOTCH1 RECEPTOR; PREDNISONE; RETROVIRUS VECTOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE ACTIVATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE NUMBER; GENE REARRANGEMENT; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC ANALYSIS; HUMAN; INFANT; LYMPHOCYTE SUBPOPULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTO ONCOGENE; RETROVIRUS; SCHOOL CHILD; STEM CELL; T CELL LEUKEMIA; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, X; CYCLINS; DNA-BINDING PROTEINS; GAMMARETROVIRUS; GENE THERAPY; HUMANS; INFANT; JANUS KINASE 3; LEUKEMIA, T-CELL; METALLOPROTEINS; MODELS, BIOLOGICAL; MUTATION; RECEPTORS, INTERLEUKIN-2; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 51349090473     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35700     Document Type: Article

References (55)

1. Cavazzana-Calvo, M., et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:669-672.
2. Hacein-Bey-Abina, S., et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346:1185-1193.
3. Aiuti, A., et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:2410-2413.
4. Gaspar, H.B., et al. 2004. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 364:2181-2187.
5. Hacein-Bey-Abina, S., et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302:415-419.
6. Wu, X., Li, Y., Crise, B., and Burgess, S.M. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science. 300:1749-1751.
7. Mitchell, R.S., et al. 2004. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2:E234.
8. Lewinski, M.K., et al. 2006. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2:e60.
9. Bushman, F., et al. 2005. Genome-wide analysis of retroviral DNA integration. Nat. Rev. Microbiol. 3:848-858.
10. Oudot, C., et al. 2008. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J. Clin. Oncol. 26:1496-1503.
11. Schrappe, M., Beier, R., and Burger, B. 2002. New treatment strategies in childhood acute lymphoblastic leukaemia. Best Pract. Res. Clin. Haematol. 15:729-740.
12. Kamps, W.A., et al. 1999. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood. 94:1226-1236.
13. Asselin, B., et al. 2001. Improved event-free survival (efs) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study [abstract]. Proc. Am. Soc. Clin. Oncol. 20:367a.
14. Goldberg, J.M., et al. 2003. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J. Clin. Oncol. 21:3616-3622.
15. Printz, M., et al. 1995. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays. Gene Ther. 2:143-150.
16. Lim, A., et al. 2002. Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses. J. Immunol. Methods. 261:177-194.
17. Aifantis, I., Buer, J., von Boehmer, H., and Azogui, O. 1997. Essential role of the pre-T cell receptor in allelic exclusion of the T cell receptor beta locus. Immunity. 7:601-607.
18. Clappier, E., et al. 2006. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia. 20:82-86.
19. Dik, W.A., et al. 2005. CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes. Leukemia. 19:1948-1957.
20. Soulier, J., et al. 2005. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 106:274-286.
21. Clappier, E., et al. 2007. The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood. 110:1251-1261.
22. Royer-Pokora, B., Loos, U., and Ludwig, W.D. 1991. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene. 6:1887-1893.
23. Haupt, Y., Alexander, W.S., Barri, G., Klinken, S.P., and Adams, J.M. 1991. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell. 65:753-763.
24. van Lohuizen, M., et al. 1991. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell. 65:737-752.
25. Jacobs, J.J., et al. 1999. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13:2678-2690.
26. Lessard, J., and Sauvageau, G. 2003. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 423:255-260.
27. Sicinska, E., et al. 2003. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell. 4:451-461.
28. Aplan, P.D., et al. 1990. Disruption of the human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science. 250:1426-1429.
29. Weng, A.P., et al. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 306:269-271.
30. Cayuela, J.M., Madani, A., Sanhes, L., Stern, M.H., and Sigaux, F. 1996. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood. 87:2180-2186.
31. Jackson, A., et al. 2000. Deletion of 6q16-q21 in human lymphoid malignancies: a mapping and deletion analysis. Cancer Res. 60:2775-2779.
32. Lahortiga, I., et al. 2007. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat. Genet. 39:593-595.
33. Armstrong, S.A., and Look, A.T. 2005. Molecular genetics of acute lymphoblastic leukemia. J. Clin. Oncol. 23:6306-6315.
34. Mullighan, C.G., et al. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 446:758-764.
35. Dave, U.P., Jenkins, N.A., and Copeland, N.G. 2004. Gene therapy insertional mutagenesis insights. Science. 303:333.
36. Aiuti, A., et al. 2007. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J. Clin. Invest. 117:2233-2240.
37. Deichmann, A., et al. 2007. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117:2225-2232.
38. Woods, N.B., Bottero, V., Schmidt, M., von Kalle, C., and Verma, I.M. 2006. Gene therapy: therapeutic gene causing lymphoma. Nature. 440:1123.
39. Pike-Overzet, K., et al. 2007. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia. 21:754-763.
40. Pike-Overzet, K., et al. 2006. Gene therapy: is IL2RG oncogenic in T-cell development? Nature. 443:E5; discussion E6-E7.
41. Thrasher, A.J., et al. 2006. Gene therapy: X-SCID transgene leukaemogenicity. Nature. 443:E5-E6; discussion E6-E7.
42. Shou, Y., Ma, Z., Lu, T., and Sorrentino, B.P. 2006. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. U. S. A. 103:11730-11735.
43. Zychlinski, D., et al. 2008. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16:718-725.
44. Montini, E., et al. 2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24:687-696.
45. Aker, M., et al. 2007. Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum. Gene Ther. 18:333-343.
46. Beillard, E., et al. 2003. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 17:2474-2486.
47. Mueller, P.R., and Wold, B. 1989. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science. 246:780-786.
48. Fors, L., Saavedra, R.A., and Hood, L. 1990. Cloning of the shark Po promoter using a genomic walking technique based on the polymerase chain reaction. Nucleic Acids Res. 18:2793-2799.
49. Wang, G.P., et al. 2008. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res. 36:e49.
50. Wang, G.P., Ciuffi, A., Leipzig, J., Berry, C.C., and Bushman, F.D. 2007. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 17:1186-1194.
51. Barr, S.D., et al. 2006. HIV integration site selection: targeting in macrophages and the effects of different routes of viral entry. Mol. Ther. 14:218-225.
52. Ciuffi, A., et al. 2006. Integration site selection by HIV-based vectors in dividing and growth-arrested IMR-90 lung fibroblasts. Mol. Ther. 13:366-373.
53. Lewinski, M.K., et al. 2005. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 79:6610-6619.
54. Schroder, A.R., et al. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 110:521-529.
55. Margulies, M., et al. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature. 437:376-380.